Successes and challenges in varicella vaccine

Therapeutic Advances in Vaccines

Volumn 2, Issue 2, 2014, Pages 39-55

  Papaloukas, Orestis ^a   Giannouli, Georgia ^a   Papaevangelou, Vassiliki ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Epidemiology; Herpes zoster incidence; Varicella vaccination; Varicella zoster virus; VZV cellular immunity

Indexed keywords

EID: 84920101640     PISSN: 20510136     EISSN: None     Source Type: Journal    
DOI: 10.1177/2051013613515621     Document Type: Review

References (143)

1. AAP (2007) Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 120: 221–231.
2. ACIP (1996) Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 45(RR-11): 1–36.
3. ACIP (2008) Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 57: 258–260.
4. Aebi, C., Fischer, K., Gorgievski, M., Matter, L. and Muhlemann, K. (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19: 3097–3103.
5. Arvin, A. (1996) Varicella-zoster virus. Clin Microbiol Rev 9: 361–381.
6. Baxter, R., Ray, P., Tran, T., Black, S., Shinefield, H., Coplan, P. et al. (2013) Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics 131: e1389–e1396.
7. Bayer, O., Heininger, U., Heiligensetzer, C. and von Kries, R. (2007) Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 25: 6655–6660.
8. Beutels, P., Clara, R., Tormans, G., Van Doorslaer, E. and Van Damme, P. (1996) Costs and benefits of routine varicella vaccination in German children. J Infect Dis 174(Suppl. 3): S335–S341.
9. Black, S., Ray, P., Shinefield, H., Saddier, P. and Nikas, A. (2008) Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis 197(Suppl. 2): S139–S142.
10. Bloch, K. and Johnson, J. (2012) Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster. J Infect Dis 205: 1331–1333.
11. Boelle, P. and Hanslik, T. (2002) Varicella in nonimmune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129: 599–606.
12. Bonanni, P., Boccalini, S., Bechini, A. and Banz, K. (2008) Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine 26: 5619–5626.
13. Bonanni, P., Breuer, J., Gershon, A., Gershon, M., Hryniewicz, W., Papaevangelou, V. et al. (2009) Varicella vaccination in Europe - taking the practical approach. BMC Med 7: 26.
14. Bonanni, P., Gershon, A., Gershon, M., Kulcsar, A., Papaevangelou, V., Rentier, B. et al. (2013) Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J 32: e305–e313.
15. Bonhoeffer, J., Baer, G., Muehleisen, B., Aebi, C., Nadal, D., Schaad, U. et al. (2005) Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr 164: 366–370.
16. Breuer, J., Schmid, D. and Gershon, A. (2008) Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 197(Suppl. 2): S147–S151.
17. Brisson, M. and Edmunds, W. (2002) The costeffectiveness of varicella vaccination in Canada. Vaccine 20: 1113–1125.
18. Brisson, M., Edmunds, W., Gay, N., Law, B. and De Serres, G. (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125: 651–669.
19. Brisson, M., Edmunds, W., Law, B., Gay, N., Walld, R., Brownell, M. et al. (2001) Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127: 305–314.
20. Brisson, M., Melkonyan, G., Drolet, M., De Serres, G., Thibeault, R. and De Wals, P. (2010) Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 28: 3385–3397.
21. Carville, K., Riddell, M. and Kelly, H. (2010) A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 28: 2532–2538.
22. CDC (1995) Licensure of varicella virus vaccine, live. MMWR Morb Mortal Wkly Rep 44: 264.
23. CDC (2008) Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 57: 258–260.
24. Chaves, S., Gargiullo, P., Zhang, J., Civen, R., Guris, D., Mascola, L. et al. (2007) Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356: 1121–1129.
25. Chaves, S., Haber, P., Walton, K., Wise, R., Izurieta, H., Schmid, D. et al. (2008) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis 197(Suppl. 2): S170–S177.
26. Chaves, S., Lopez, A., Watson, T., Civen, R., Watson, B., Mascola, L. et al. (2011) Varicella in infants after implementation of the US varicella vaccination program. Pediatrics 128: 1071–1077.
27. Chen, J., Gershon, A., Li, Z., Lungu, O. and Gershon, M. (2003) Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol 70(Suppl. 1): S71–S78.
28. Choo, P., Donahue, J., Manson, J. and Platt, R. (1995) The epidemiology of varicella and its complications. J Infect Dis 172: 706–712.
29. Civen, R., Chaves, S., Jumaan, A., Wu, H., Mascola, L., Gargiullo, P. et al. (2009) The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 28: 954–959.
30. Cohrs, R., Mehta, S., Schmid, D., Gilden, D. and Pierson, D. (2008) Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol 80: 1116–1122.
31. Coudeville, L., Paree, F., Lebrun, T. and Sailly, J. (1999) The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17: 142–151.
32. Critselis, E., Nastos, P., Theodoridou, K., Theodoridou, M., Tsolia, M., Hadjichristodoulou, C. et al. (2012a) Time trends in pediatric hospitalizations for varicella infection are associated with climatic changes: a 22-year retrospective study in a tertiary Greek referral center. PLoS One 7(12): e52016.
33. Critselis, E., Nastos, P., Theodoridou, K., Theodoridou, M., Tsolia, M. and Papaevangelou, V. (2012b) Association between variations in the epidemiology of varicella infection and climate change in a temperate region. In 30th Annual Meeting of the European Society For Paediatric Infectious Diseases, 8–12 May 2012, Thessaloniki, Greece.
34. Davis, M., Patel, M. and Gebremariam, A. (2004) Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 114: 786–792.
35. Deguen, S., Chau, N. and Flahault, A. (1998) Epidemiology of chickenpox in France (1991–1995). J Epidemiol Community Health 52(Suppl. 1): 46S-49S.
36. Devlin, M., Gilden, D., Mahalingam, R., Dueland, A. and Cohrs, R. (1992) Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis 165: 619–622.
37. Diez Domingo, J., Ridao, M., Latour, J., Ballester, A. and Morant, A. (1999) A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17: 1306–1311.
38. Doerr, H. (2013) Progress in VZV vaccination? Some concerns. Med Microbiol Immunol, in press.
39. Dubos, F., Grandbastien, B., Hue, V., Hospital Network for Evaluating Management of Common Childhood Diseases and Martinot, A. (2007) Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era. Epidemiol Infect 135: 131–138.
40. Enders, G., Miller, E., Cradock-Watson, J., Bolley, I. and Ridehalgh, M. (1994) Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343: 1548–1551.
41. Furuta, Y., Ohtani, F., Sawa, H., Fukuda, S. and Inuyama, Y. (2001) Quantitation of varicella-zoster virus DNA in patients with Ramsay Hunt syndrome and zoster sine herpete. J Clin Microbiol 39: 2856–2859.
42. Gabutti, G., Penna, C., Rossi, M., Salmaso, S., Rota, M., Bella, A. et al. (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126: 433–440.
43. Galil, K., Brown, C., Lin, F. and Seward, J. (2002a) Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J 21: 931–935.
44. Galil, K., Fair, E., Mountcastle, N., Britz, P. and Seward, J. (2002b) Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 186: 102–105.
45. Garnett, G., Cox, M., Bundy, D., Didier, J. and St Catharine, J. (1993) The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect 110: 361–372.
46. Gershon, A. and Gershon, M. (2010) Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol 342: 359–372.
47. Gershon, A., Levin, M., Weinberg, A., Song, L., LaRussa, P., Steinberg, S. et al. (2009) A phase I–II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virusinfected children with previous varicella. Pediatr Infect Dis J 28: 653–655.
48. Gershon, A., Steinberg, S., Gelb, L., Galasso, G., Borkowsky, W., LaRussa, P. et al. (1984) Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 252: 355–362.
49. Giammanco, G., Ciriminna, S., Barberi, I., Titone, L., Lo Giudice, M. and Biasio, L. (2009) Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years. Euro Surveill 14(35): 19321.
50. Gnann, J., Jr and Whitley, R. (2002) Clinical practice. Herpes zoster. N Engl J Med 347: 340–346.
51. Goldman, G. (2005) Universal varicella vaccination: efficacy trends and effect on herpes zoster. International journal of toxicology 24(4): 205–213.
52. Guris, D., Jumaan, A., Mascola, L., Watson, B., Zhang, J., Chaves, S. et al. (2008) Changing varicella epidemiology in active surveillance sites–United States, 1995–2005. J Infect Dis 197(Suppl. 2): S71–S75.
53. Hambleton, S. and Gershon, A. (2005) Preventing varicella-zoster disease. Clin Microbiol Rev 18: 70–80.
54. Hohle, M., Siedler, A., Bader, H., Ludwig, M., Heininger, U. and Von Kries, R. (2011) Assessment of varicella vaccine effectiveness in Germany: a time-series approach. Epidemiol Infect 139: 1710–1719.
55. Jacobsen, S., Ackerson, B., Sy, L., Tran, T., Jones, T., Yao, J. et al. (2009) Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 27: 4656–4661.
56. Jardine, A., Conaty, S. and Vally, H. (2011) Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiology and Infection 139(5): 658–665.
57. Josephson, A. and Gombert, M. (1988) Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 158: 238–241.
58. Jumaan, A., Yu, O., Jackson, L., Bohlke, K., Galil, K. and Seward, J. (2005) Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 191: 2002–2007.
59. Katsafadou, A., Ferentinos, G., Constantopoulos, A. and Papaevangelou, V. (2008) The epidemiology of varicella in school-aged Greek children before the implementation of universal vaccination. Eur J Clin Microbiol Infect Dis 27: 223–226.
60. Katsafadou, A., Kallergi, K., Ferentinos, G., Goulioti, T., Foustoukou, M. and Papaevangelou, V. (2009) Presumptive varicella vaccination is warranted in Greek adolescents lacking a history of disease or household exposure. Eur J Pediatr 168: 23–25.
61. Kimura, H., Kido, S., Ozaki, T., Tanaka, N., Ito, Y., Williams, R. et al. (2000) Comparison of quantitations of viral load in varicella and zoster. J Clin Microbiol 38: 2447–2449.
62. Klein, N., Fireman, B., Yih, W., Lewis, E., Kulldorff, M., Ray, P. et al. (2010) Measles–mumps–rubella–varicella combination vaccine and the risk of febrile seizures. Pediatrics 126(1): e1–e8.
63. Kuter, B., Matthews, H., Shinefield, H., Black, S., Dennehy, P., Watson, B. et al. (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23: 132–137.
64. Lee, B. (1998) Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 3: 886–890.
65. Leung, J., Harpaz, R., Molinari, N., Jumaan, A. and Zhou, F. (2011) Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 52: 332–340.
66. Levin, M., Dahl, K., Weinberg, A., Giller, R., Patel, A. and Krause, P. (2003) Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 188: 954–959.
67. Levy, O., Orange, J., Hibberd, P., Steinberg, S., LaRussa, P., Weinberg, A. et al. (2003) Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 188: 948–953.
68. Liese, J., Grote, V., Rosenfeld, E., Fischer, R., Belohradsky, B. and v Kries, R. for the ESPED Varicella Study Group (2008) The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J 27: 119–124.
69. Liyanage, N., Fernando, S., Malavige, G., Mallikahewa, R., Sivayogan, S., Jiffry, M. et al. (2007) Seroprevalence of varicella zoster virus infections in Colombo district, Sri Lanka. Indian J Med Sci 61: 128–134.
70. Ljungman, P., Lonnqvist, B., Gahrton, G., Ringden, O., Sundqvist, V. and Wahren, B. (1986) Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 153: 840–847.
71. Lolekha, S., Tanthiphabha, W., Sornchai, P., Kosuwan, P., Sutra, S., Warachit, B. et al. (2001) Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg 64: 131–136.
72. Lopez, A., Kolasa, M. and Seward, J. (2008) Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. J Infect Dis 197(Suppl. 2): S76–S81.
73. Luman, E., Ching, P., Jumaan, A. and Seward, J. (2006) Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics 117: 999–1008.
74. Mandal, B., Mukherjee, P., Murphy, C., Mukherjee, R. and Naik, T. (1998) Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis 178(Suppl. 1): S52–S54.
75. Marin, M., Guris, D., Chaves, S., Schmid, S. and Seward, J. for the Advisory Committee on Immunization Practices et al. (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-4): 1–40.
76. Marin, M., Watson, T., Chaves, S., Civen, R., Watson, B., Zhang, J. et al. (2008) Varicella among adults: data from an active surveillance project, 1995–2005. J Infect Dis 197(Suppl. 2): S94–S100.
77. Marin, M., Zhang, J. and Seward, J. (2011) Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 128: 214–220.
78. McCauley, M., Stokley, S., Stevenson, J. and Fishbein, D. (2008) Adolescent vaccination: coverage achieved by ages 13–15 years, and vaccinations received as recommended during ages 11–12 years, National Health Interview Survey 1997–2003. J Adolesc Health 43: 540–547.
79. Mehta, S., Cohrs, R., Forghani, B., Zerbe, G., Gilden, D. and Pierson, D. (2004) Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 72: 174–179.
80. Meyer, P., Seward, J., Jumaan, A. and Wharton, M. (2000) Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis 182: 383–390.
81. Miller, E., Vardien, J. and Farrington, P. (1993) Shift in age in chickenpox. Lancet 341: 308–309.
82. Mongua-Rodriguez, N., Diaz-Ortega, J., Garcia-Garcia, L., Pina-Pozas, M., Ferreira-Guerrero, E., Delgado-Sanchez, G. et al. (2013) A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome. Vaccine 31: 2145–2151.
83. Nader, S., Bergen, R., Sharp, M. and Arvin, A. (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171: 13–17.
84. Nagel, M., Choe, A., Cohrs, R., Traktinskiy, I., Sorensen, K., Mehta, S. et al. (2011) Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis 204: 820–824.
85. Nardone, A., de Ory, F., Carton, M., Cohen, D., van Damme, P., Davidkin, I. et al. (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25: 7866–7872.
86. Nelson, M., Britt, H. and Harrison, C. (2010) Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. The Medical journal of Australia 193(2): 110–113.
87. Ngai, A., Staehle, B., Kuter, B., Cyanovich, N., Cho, I., Matthews, H. et al. (1996) Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 15: 49–54.
88. Nguyen, H., Jumaan, A. and Seward, J. (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352: 450–458.
89. Papaevangelou, V., Quinlivan, M., Lockwood, J., Papaloukas, O., Sideri, G., Critselis, E. et al. (2013) Subclinical VZV reactivation in immunocompetent children hospitalized in the ICU associated with prolonged fever duration. Clin Microbiol Infect 19: E245–E251.
90. Paryani, S. and Arvin, A. (1986) Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 314: 1542–1546.
91. Patel, M., Gebremariam, A. and Davis, M. (2008) Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infection Control and Hospital Epidemiology: The official journal of the Society of Hospital Epidemiologists of America 29(12): 1157–1163.
92. Pinot de Moira, A. and Nardone, A. (2005) Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill 10: 43–45.
93. Plotkin, S., Arbetter, A. and Starr, S. (1985) The future of varicella vaccine. Postgrad Med J 61(Suppl. 4): 155–162.
94. Pollock, J. and Golding, J. (1993) Social epidemiology of chickenpox in two British national cohorts. J Epidemiol Community Health 47: 274–281.
95. Provost, P., Krah, D., Kuter, B., Morton, D., Schofield, T., Wasmuth, E. et al. (1991) Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 9: 111–116.
96. Quian, J., Ruttimann, R., Romero, C., Dall’Orso, P., Cerisola, A., Breuer, T. et al. (2008) Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997–2005. Arch Dis Child 93: 845–850.
97. Quinlivan, M., Sengupta, N., Papaevangelou, V., Sauerbrei, A., Grillner, L., Rousseva, R. et al. (2013) Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United Kingdom and continental Europe. J Infect Dis 207: 588–593.
98. Quinlivan, M., Ayres, K., Ran, H., McElwaine, S., Leedham-Green, M., Scott, F. et al. (2007) Effect of viral load on the outcome of herpes zoster. J Clin Microbiol 45: 3909–3914.
99. Quinlivan, M., Ayres, K., Kelly, P., Parker, S., Scott, F., Johnson, R. et al. (2011) Persistence of varicellazoster virus viraemia in patients with herpes zoster. J Clin Virol 50: 130–135.
100. Rawson, H., Crampin, A. and Noah, N. (2001) Deaths from chickenpox in England and Wales 1995–7: analysis of routine mortality data. BMJ 323: 1091–1093.
101. Reynolds, M., Watson, B., Plott-Adams, K., Jumaan, A., Galil, K., Maupin, T. et al. (2008) Epidemiology of varicella hospitalizations in the United States, 1995–2005. J Infect Dis 197(Suppl. 2): S120–S126.
102. Rimland, D. and Moanna, A. (2010) Increasing incidence of herpes zoster among Veterans. Clin Infect Dis 50: 1000–1005.
103. Ross, A. (1962) Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 267: 369–376.
104. Rozenbaum, M., van Hoek, A., Vegter, S. and Postma, M. (2008) Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 7: 753–782.
105. Schmid, D. and Jumaan, A. (2010) Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 23: 202–217.
106. Schunemann, S., Mainka, C. and Wolff, M. (1998) Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology 41: 98–102.
107. Scuffham, P., Lowin, A. and Burgess, M. (1999) The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18: 407–415.
108. Sengupta, N., Booy, R., Schmitt, H., Peltola, H., Van-Damme, P., Schumacher, R. et al. (2008) Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr 167: 47–55.
109. Seward, J., Marin, M. and Vazquez, M. (2008) Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 197(Suppl. 2): S82–S89.
110. Seward, J., Watson, B., Peterson, C., Mascola, L., Pelosi, J., Zhang, J. et al. (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287: 606–611.
111. Shah, S., Wood, S., Luan, X. and Ratner, A. (2010) Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J 29: 199–204.
112. Shapiro, E., Vazquez, M., Esposito, D., Holabird, N., Steinberg, S., Dziura, J. et al. (2011) Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 203: 312–315.
113. Siedler, A. and Arndt, U. (2010) Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill 15(13): article 4.
114. Silber, J., Chan, I., Wang, W., Matthews, H. and Kuter, B. (2007) Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12–14 months of age versus 15–23 months of age. Pediatr Infect Dis J 26: 572–576.
115. Sloan, D. and Burlison, A. (1992) Shift in age in chickenpox. Lancet 340: 974.
116. Soarez, P., Novaes, H. and Sartori, A. (2009) Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making? Cad Saude Publica 25(Suppl. 3): S401–S414.
117. Socan, M. and Blasko, M. (2007) Surveillance of varicella and herpes zoster in Slovenia, 1996–2005. Euro Surveill 12(2).
118. Suzuki, K., Yoshikawa, T., Tomitaka, A., Matsunaga, K. and Asano, Y. (2004) Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis 189: 1009–1012.
119. Takahashi, M., Kamiya, H., Baba, K., Asano, Y., Ozaki, T. and Horiuchi, K. (1985) Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 61(Suppl. 4): 61–67.
120. Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y. and Yazaki, T. (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 1288–1290.
121. Tan, B., Bettinger, J., McConnell, A., Scheifele, D., Halperin, S., Vaudry, W. et al. (2012) The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000–2008. Pediatr Infect Dis J 31: 956–963.
122. Tanuseputro, P., Zagorski, B., Chan, K.J. and Kwong, J.C. (2011) Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29(47): 8580–8584.
123. Thiry, N., Beutels, P., Tancredi, F., Romano, L., Zanetti, A., Bonanni, P. et al. (2004) An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 22: 3546–3562.
124. Tseng, H., Smith, N., Marcy, S., Sy, L. and Jacobsen, S. (2009) Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002–2008. Pediatr Infect Dis J 28: 1069–1072.
125. Tseng, H., Tan, H., Chang, C., Wang, L., Yang, S., Liau, M. et al. (2005) A seroepidemiology study of varicella among children aged 0–12 years in Taiwan. Southeast Asian J Trop Med Public Health 36: 1201–1207.
126. Ultsch, B., Siedler, A., Rieck, T., Reinhold, T., Krause, G. and Wichmann, O. (2011) Herpes zoster in Germany: Quantifying the burden of disease. BMC Infectious Diseases 11: 173.
127. Valerio, L., Escriba, J., Fernandez-Vazquez, J., Roca, C., Milozzi, J., Solsona, L. et al. (2009) Biogeographical origin and varicella risk in the adult immigration population in Catalonia, Spain (2004–2006). Euro Surveill 14(37).
128. Van Damme, P., Kane, M. and Meheus, A. (1997) Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 314: 1033–1036.
129. Vazquez, M., LaRussa, P., Gershon, A., Niccolai, L., Muehlenbein, C., Steinberg, S. et al. (2004) Effectiveness over time of varicella vaccine. JAMA 291: 851–855.
130. Verstraeten, T., Jumaan, A., Mullooly, J., Seward, J., Izurieta, H., DeStefano, F. et al. (2003) A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 112(2): e98–e103.
131. Viner, K., Perella, D., Lopez, A., Bialek, S., Newbern, C., Pierre, R. et al. (2012) Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 205: 1336–1341.
132. Wagenpfeil, S., Neiss, A., Banz, K. and Wutzler, P. (2004) Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect 10: 425–430.
133. Watson, B., Boardman, C., Laufer, D., Piercy, S., Tustin, N., Olaleye, D. et al. (1995a) Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 20: 316–319.
134. Watson, B., Rothstein, E., Bernstein, H., Arbeter, A., Arvin, A., Chartrand, S. et al. (1995b) Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 172: 217–219.
135. Weinberg, A., Lazar, A., Zerbe, G., Hayward, A., Chan, I., Vessey, R. et al. (2010) Influence of age and nature of primary infection on varicella-zoster virusspecific cell-mediated immune responses. J Infect Dis 201: 1024–1030.
136. Weinberg, A. and Levin, M. (2010) VZV T cellmediated immunity. Curr Top Microbiol Immunol 342: 341–357.
137. WHO (1998) Varicella vaccines. WHO position paper. Wkly Epidemiol Rec 73: 241–248.
138. Wilson, A., Sharp, M., Koropchak, C., Ting, S. and Arvin, A. (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165: 119–126.
139. Wong, C., Taylor, J., Wright, J., Opel, D. and Katzenellenbogen, R. (2013) Missed opportunities for adolescent vaccination, 2006–2011. J Adolesc Health, in press.
140. Yawn, B., Yawn, R. and Lydick, E. (1997) Community impact of childhood varicella infections. J Pediatr 130: 759–765.
141. Yih, W., Brooks, D., Lett, S., Jumaan, A., Zhang, Z., Clements, K. et al. (2005) The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 5: 68.
142. Zhou, F., Harpaz, R., Jumaan, A., Winston, C. and Shefer, A. (2005) Impact of varicella vaccination on health care utilization. JAMA 294: 797–802.
143. Ziebold, C., von Kries, R., Lang, R., Weigl, J. and Schmitt, H. (2001) Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics 108(5): E79.